Bial - Portela C S.A.
Quick facts
Marketed products
- ESL · Neurology
ESL (eslicarbazepine acetate) is a voltage-gated sodium channel blocker that reduces neuronal excitability and stabilizes seizure threshold. - L-DOPA/DDCI · Neurology
L-DOPA is converted to dopamine in the brain to replace deficient neurotransmitter levels, while DDCI (a decarboxylase inhibitor) prevents premature conversion of L-DOPA in the periphery, allowing more to reach the central nervous system. - levodopa/dopa decarboxylase inhibitor · Neurology
Levodopa is converted to dopamine in the brain to replace deficient neurotransmitter levels, while the dopa decarboxylase inhibitor prevents premature conversion in the periphery, allowing more levodopa to reach the brain. - Ongentys · Neuroscience
Phase 3 pipeline
- ESL - Part II · Neurology
ESL (eslicarbazepine acetate) is a voltage-gated sodium channel blocker that reduces neuronal excitability to prevent seizures.
Phase 2 pipeline
- BIA 2-093
- BIA 3-202
- Comtan®
- Contraceptives, Oral, Combined
- ESL Banana taste
- ESL Grape taste
- ESL Tutti-Frutti taste · Diabetes
ESL works by inhibiting the enzyme dipeptidyl peptidase-4 (DPP-4). - SL-APO
Phase 1 pipeline
- [14C]-BIA 9-1067
- BIA 5-1058 and Furosemide
- BIA 5-453
- BIA 6-512
- BIA 9-1067 25 mg
- BIA 9-1067 30 mg
- BIA 9-1067 5 mg
- BIA 9-1067 micronized
- BIA 9-1067 non-micronized
- eslicarbazepine acetate and Microginon®
- Madopar® 125
- Madopar® 250
- Madopar® HBS
- Madopar® HBS 125
- Microginon®
- Prolopa®
- R-licarbazepine
- S-licarbazepine
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: